SCP Analysis Of The Market Performance Of Pharmaceutical Industry In China Based On Empirical Research

Pharmaceutical manufacturing industry is an important industry for the people's livelihood, with the 2009 health system reform, in recent years, China's pharmaceutical manufacturing obtained the rapid development momentum, also with the growth of China's population, the full liberalization of the implementation of the two child policy, and aging population growth, people's health consciousness enhancement, the Chinese medicine manufacturing industry is facing the huge and growing demand. At present, China's pharmaceutical industry R & D investment facing low intensity, industry concentration effects of economies of scale and other issues, to some extent restricted the supply of China's pharmaceutical market.To of our country current medicine manufacturing industry have a more clear and objective understanding found in recent years the development of rule, the meso research in the field of industrial organization theory, SCP paradigm, launches a meticulous analysis of Chinese pharmaceutical manufacturing industry market structure, market behavior, involving to the industry concentration degree, product differentiation, enter barrier, intensity of R & D and M & A activity and found the current development of the pharmaceutical industry in our country is the joy and sorrow, the overall showing a flourishing development momentum, but there are still with the power of a lot of problems, the need for government and enterprises.On this basis, this paper introduces the commonly used method of studying the market performance of principal component analysis, access to relevant data China "Statistical Yearbook" in the website of the National Bureau of statistics, the economic index of 11 normalized, combined with the 2006 to 2014 this 9 years of data, the empirical analysis of the model, finally the past nine years found that China's pharmaceutical industry overall more positive, but its growth rate is relatively different, in 2007 2008, the performance is relatively low, should be related to the global economic crisis in 2011, 2012, in particular the rapid development momentum, closely related to implementation and in 2009 after the reform of the medical and health system, after 2013 in 2014, the growth rate started to slow down, we need to pay attention to the relevant government departments and other parties.